BCAX
NASD Bicara Therapeutics Inc.$16.78 ↑ +0.00 (+0.00%) Trading Up from the previous close of $16.78, $1.00 below the day’s high of $17.78
- YTD change
- -0.30%
- vs 20-day SMA
- -10.11%
- vs 200-day SMA
- -21.21%
Price ranges
Price & Performance
-7.23 (-30.11%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 45.9% away from all-time highs of $30.99
- BCAX is down 0% since the beginning of the year
- BCAX is down 10% over the past 12 months
- BCAX is down 26% over the past 1 month
- 18% of all BCAX investors are betting against BCAX
BCAX reads poor: price sits below both the 20- and 200-day averages, the 12-month move is -8.1%.
- Previous minute
- +$0.00
- Last hour
- +$0.00
- Last 5 days
- -2.78%
- vs 8-day SMA
- -2.28%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Bicara Therapeutics, Inc. is a clinical-stage biotechnology company and develops biologics engineered to combine the precision of well validated, tumor-targeting antibodies with the power of tumor microenvironment modulators. The company’s bi-functional antibodies are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, offering the potential for synergistic therapeutic impact at the site of the tumor. Its products include BCA101, a first-in-class EGFR/TGF-ß-trap bifunctional antibody in clinical development for multiple tumor types. The company was founded on December 12, 2018 and is headquartered in Boston, MA.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
